Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer - Wikidata - thesis-toulmin - TriplyDB

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

http://www.wikidata.org/entity/Q28186303

about

Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer Venous thromboembolic disease VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Diagnosis and treatment of deep-vein thrombosis Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review Pancreatic cancer and thromboembolic disease, 150 years after Trousseau Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art Trousseau's syndrome: cancer-associated thrombosis Assessing the risk of recurrent venous thromboembolism--a practical approach Heparin in malignant glioma: review of preclinical studies and clinical results Anticoagulants in cancer Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation Venous thromboembolism in cancer patients: an underestimated major health problem The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials Endovascular Interventions for Acute and Chronic Lower Extremity Deep Venous Disease: State of the Art Predicting the risk of venous thromboembolism recurrence Medical management of brain tumors and the sequelae of treatment.Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities What is the Best Treatment for a Cancer Patient with Thrombosis?Cerebral ischemic events in patients with pancreatic cancer: A retrospective cohort study of 17 patients and a literature review Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism Guidance for the prevention and treatment of cancer-associated venous thromboembolism Management of venous thromboembolism: an update Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism Thrombosis in multiple myeloma Guidelines on oral anticoagulation with warfarin - fourth edition The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials Portal vein thrombosis: When to treat and how?Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thro Deep vein thrombosis: current status and nanotechnology advances.

P2860

Q24187370-2524A1CB-F197-4417-BAFB-2D7A6415F56B Q24194904-5C79C739-BAA8-4654-A5A6-7B47A9254D75 Q24202706-C8FB17CA-978C-4699-9811-001847B80DD0 Q24236620-D248E703-3159-466C-8797-FD46E72CB151 Q24243286-D8C93027-8D66-4A84-945D-328A1695E6F1 Q24631121-9AED3BD4-36CB-4998-9A12-DF78A7F887A4 Q24632982-3F7E56F1-29AB-49D0-B7A2-BD678867149D Q24633053-B005FF8F-06B1-4D15-BA53-1C865B05A2AD Q24673847-63B73CFB-8214-4352-AC16-1BAC0702C9E6 Q26741697-5CDBB50C-0F01-493C-B586-0F7D8B4617EA Q26749273-029277BD-5E30-4FC6-A513-C9925BA65A23 Q26753853-D66D7B3A-2D72-44BA-A195-566B1EA4063B Q26775634-3DA22142-04BA-4570-8CD0-D3757B779036 Q26776112-F7D7C14C-5B1C-43E9-BA6A-0FE4E858774D Q26778607-4724752C-D62E-4EF1-8438-C6C35973AF2D Q26796430-84FF086A-99E4-4C4B-A49A-EDEC32159D5A Q26821781-0359B41B-2C59-4B3D-9311-C5E983CA5132 Q26825228-04C396B4-254C-460D-A75C-F9BCAC5123F1 Q26825608-A7050782-9139-4458-9B9C-913538F6AA70 Q26852015-E5185AD1-33F8-4B8D-BFC1-3DACB22B135F Q26852293-8B8422D0-8D7C-4CC3-BD37-6910835F6472 Q26864863-8CF5FEF2-DAD6-4B61-B65A-2B4014971C23 Q26865059-90AADBA4-954F-46F7-8C73-B00719EC7CF5 Q26992174-B4D13ED6-EF0E-4A0E-BDF6-67230F472A1C Q26992262-34E8E118-722A-4CB9-A143-DCD64C3E6A4F Q27001528-7826BB9B-705A-4839-83F4-CE63447246C3 Q27009514-5E6D80A9-5BC6-40FE-9230-4A13DF7006EB Q27314885-74089BC6-DBFD-4D81-93F8-FADE5E12CBB3 Q28066527-2ACBF095-1587-46A9-8E4D-ACF6573E57B1 Q28069131-58B84425-1931-4026-8795-CE3BCE27D354 Q28071443-9E94E4F0-FC73-49CF-BFAB-9DE3542AAF5D Q28074248-D31F29E5-FA4D-4C07-832D-4EE1B1733077 Q28076077-19BE7A97-6CD3-4326-B6C3-D686C42A5598 Q28079081-648ED7E1-B337-4CE1-BE7A-36E5968AC678 Q28219961-616AC10F-80B6-4CB8-B2F2-A465BB85A787 Q28240666-94C0D9F0-4C85-4D18-AFD0-6311744A5372 Q28296482-025E88FC-521E-4DEA-B3C8-7CE3B8604014 Q30278059-7B5EB1A3-A20B-4D24-AF34-9AEEB46A8869 Q30315531-63E67D30-61C0-4F12-AF06-9245AB4FE92B Q30369732-1E712E42-62B9-4660-B376-BD04BE11AF63

P2860

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

http://www.wikidata.org/entity/Q28186303

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Low-molecular-weight heparin v ...... bolism in patients with cancer

@ast

Low-molecular-weight heparin v ...... bolism in patients with cancer

@en

Low-molecular-weight heparin v ...... bolism in patients with cancer

@nl

type

label

Low-molecular-weight heparin v ...... bolism in patients with cancer

@ast

Low-molecular-weight heparin v ...... bolism in patients with cancer

@en

Low-molecular-weight heparin v ...... bolism in patients with cancer

@nl

prefLabel

Low-molecular-weight heparin v ...... bolism in patients with cancer

@ast

Low-molecular-weight heparin v ...... bolism in patients with cancer

@en

Low-molecular-weight heparin v ...... bolism in patients with cancer

@nl

P1433

Q28186303-FB3D29AB-07F2-4CE2-8FEA-3ED6970C7CFC

P1476

Q28186303-19B4A18C-ED2C-44CE-AEE1-A0C9682A19D3

P2093

Q28186303-03D6279A-994F-4927-86CD-CEA767FE5EB9

Q28186303-0CCB2075-29C6-4011-8EF6-DAA2B044CC00

Q28186303-0EBF287C-0DA7-47CD-B252-BFCF0691DE9A

Q28186303-1D9B3EFF-8627-49CA-99EA-0C909AE5E684

Q28186303-1F8351FD-00DC-482E-82A2-6002232E986F

Q28186303-46290867-7220-4383-8005-4C9CCC9630CF

Q28186303-A5B7EBC5-9212-4222-BEE2-80DF0E60DFF2

Q28186303-ADE79A33-3816-412A-827C-98C0C7A605EE

Q28186303-C98CE7B3-11ED-422A-B1D7-CFC1C5DA7614

Q28186303-E2B1FC3E-AE2D-45F8-9CAA-73AEE2F61F31

P304

Q28186303-40BC1A37-7421-483A-AC43-8F555CC13464

P31

Q28186303-AC624DAA-38C2-4886-AE23-6114DE0430EC

P3181

Q28186303-460222CD-0C9F-415D-B3DE-D866DE694E9C

P356

Q28186303-4B07262B-0214-40F0-98A6-2ED0723B763C

P407

Q28186303-5C04C066-1502-41D8-8467-D7E237FBC5EE

P433

Q28186303-33CC6D9F-60E3-4CD8-BF23-C7BEFB2AFC99

P478

Q28186303-242A8D5B-1137-4E62-90B7-6F11D3AC8404

P577

Q28186303-56461B9E-4CFA-4E05-B0C2-39805F4C8035

P5875

Q28186303-99078E39-DA0B-404B-8E54-4DF42DEAF596

P698

Q28186303-CA964B3A-04F9-4177-B5CE-654A3029C485

P921

Q28186303-24063839-59CD-42EA-9DCA-1091FACA97CD

P3181

P356

P1433

The New England Journal of Medicine

P1476

Low-molecular-weight heparin v ...... bolism in patients with cancer

@en

P2093

Agnes Y Y Lee

http://www.w3.org/2001/XMLSchema#string

Ajay K Kakkar

http://www.w3.org/2001/XMLSchema#string

Chris Bowden

http://www.w3.org/2001/XMLSchema#string

Frederick R Rickles

http://www.w3.org/2001/XMLSchema#string

Jim A Julian

http://www.w3.org/2001/XMLSchema#string

Mark N Levine

http://www.w3.org/2001/XMLSchema#string

Martin Prins

http://www.w3.org/2001/XMLSchema#string

Michael Gent

http://www.w3.org/2001/XMLSchema#string

Michael J Kovacs

http://www.w3.org/2001/XMLSchema#string

Ross I Baker

http://www.w3.org/2001/XMLSchema#string

P304

146-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

543436

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA025313

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

349

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10667478

http://www.w3.org/2001/XMLSchema#string

P698

12853587

http://www.w3.org/2001/XMLSchema#string

P921